A study on the use of tacrolimus eye oitment (0.03%) in allergic eye disease

---

Original Article

Author Details : Vasudha Damle, Prakash Chand Agarwal*

Volume : 5, Issue : 4, Year : 2019

Article Page : 259-263

https://doi.org/10.18231/j.ijooo.2019.059

Suggest article by email

Get Permission

---

Abstract

Aim: To study the effect of 0.03% tacrolimus eye ointment in allergic eye disease
Materials and Methods: This prospective study was conducted on patients suffering from recurrent
allergic eye disease. All those patients who used steroids frequently because of recurrence or chronic
refractory cases were included in this study. We included 48 cases in this study. Tacrolimus 0.03% eye
ointment was used twice daily for 3 months and effect was seen in terms of improvement in symptoms,
signs and any recurrence if occurred after stopping treatment.
Results: Mean age of the patient was 21.04 7.02 and mean duration of allergic eye disease was 3.52
0.94. Symptoms and sign scores shown improvement after using tacrolimus eye ointment for 3 months.
Itching and redness (88% & 82% respectively) improved dramatically at the end of 1 month. Recurrence
was noticed at 6th month follow up in 6 cases after stopping tacrolimus eye ointment so it was restarted.
While in 42 cases (87.5%) we didn’t notice any recurrence after stopping tacrolimus eye ointment.
Conclusion: Tacrolimus eye ointment (0.03%) is effective in controlling allergic eye disease and is very
effective steroid sparing drug in chronic recurrent cases where frequent use of steroids is required.

Keywords: Allergic eye disease, Vernal keratoconjunctivitis, Perennial allergic conjunctivitis, Immunomodulators & mast cell
stabilizers.

How to cite : Damle V, Agarwal P C, A study on the use of tacrolimus eye oitment (0.03%) in allergic eye disease. IP Int J Ocul Oncol Oculoplasty 2019;5(4):259-263

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.